The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics Announces Agreement with Epic Games

25 Jul 2011 07:00

RNS Number : 9301K
Angle PLC
25 July 2011
 



For immediate release

25 July 2011

 

ANGLE plc

("ANGLE" or the "Company")

 

PORTFOLIO COMPANY GEOMERICS ANNOUNCES AGREEMENT WITH EPIC GAMES

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that its 33% owned portfolio company Geomerics, has joined Epic Games' prestigious Unreal Engine 3 Integrated Partners Programme.

The powerful integration of Geomerics premier cross-platform lighting solution, Enlighten, with Epic's award winning Unreal Engine 3 provides a com--pelling proposition for computer games developers. Through its membership in Epic's Unreal Engine 3 Integrated Partners Programme, Geomerics maintains code and feature parity for Enlighten in step with the engine as it evolves.

Epic's Unreal Engine 3 is designed to accelerate developers' productivity for computer and video games, mobile games and applications, training stimulations, 3D visualisations, digital films and animated televisions shows. Unreal Engine 3 is the current holder and five-time winner of Game Developer magasine's Best Engine award in the US. It is available across multiple platforms including iOS, Xbox360® and Playstation®3, PC, Mac and Android.

Geomerics' Enlighten empowers game developers by providing the ability to update all aspects of indirect lighting in real time, in game, on PC and console. Enlighten is optimised to run on Playstation®3, Xbox 360™ and PC. It is available as a stand-alone SDK, or pre-integrated into UE3.

 

Andrew Newland, Chief Executive of ANGLE commented: 

"This agreement with Epic, one of the world's leading and most successful games developers, is a great endorsement of Geomerics' cutting edge dynamic lighting technology. Association with Epic with its established customer base and trusted industry relationships can only be beneficial for Geomerics as it continues to grow its sales base."

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8325

Buchanan

Lisa Baderoon, Catherine Breen

 

0207 466 5000

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

 

 

About Epic Games

Epic Games, Inc., based in Cary, NC and established in 1991, develops cutting-edge games and cross-platform game engine technology. The company has created multiple million-selling, award-winning titles in its "Unreal" series, including "Unreal Tournament 3" for PC, PlayStation®3 and Xbox 360®. Epic's "Gears of War" franchise has sold more than 13 million copies worldwide and won more than 50 Game of the Year awards. Epic's Unreal Engine 3 is the five-time winner of and Hall of Fame inductee for Game Developer magazine's Best Engine Front Line Award. Unreal Engine 3 has also held the Develop Industry Excellence Award in its category for the past three years. Additional information about Epic can be obtained at www.epicgames.com.

 

About Geomerics

Geomerics, a 33% owned ANGLE portfolio company, is an innovation-led company developing cutting-edge graphics technology for the games industry. The company is based in Cambridge, UK, and has built a team that combines world class management and games industry experience with some of the UK's leading researchers. They are partners with many of the leading companies in the games industry and are currently working with developers around the world on AAA titles for release in 2011 and beyond.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRLLFESDVIFFIL
Date   Source Headline
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company
28th Feb 201212:00 pmRNSDirector Share Transfer
28th Feb 20128:00 amRNSTotal Voting Rights
27th Feb 20127:00 amRNSParsortix Research Partnership
22nd Feb 20127:00 amRNSSecond Novocellus Patent

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.